Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Sunshine Biopharma, Inc. announced the signing of a research agreement with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital, to be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through the IND-enabling studies.